Complement activation in acute coronary syndromes

APMIS

Volumn 113, Issue 3, 2005, Pages 167-174

  Iltumur, Kenan ^a   Karabulut, Aziz ^a   Toprak, Gülten ^a   Toprak, Nizamettin ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Acute coronary syndromes; Complement; Inflammation; Necrosis; Stable angina; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN; NITRATE; STREPTOKINASE; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C4; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYNDROME; TROPONIN I;

EID: 17144411103     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm1130303.x     Document Type: Article

References (36)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. van der Wal AC, Piek JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 1998;80:14-8.
3. Shah PK. New insights in the pathogenesis and prevention of acute coronary syndromes. Am J Cardiol 1997;79:17-23.
4. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of future of cardiovascular disease in apparently healty men. N Engl J Med 1997;336:973-9.
5. Müller-Eberhard HJ. Molecular organization and function of the complement system. Ann Rev Biochem 1988;57:321-47.
6. Shernan SK, Collard CD. Role of the complement system in ischaemic heart disease: potential for pharmacological intervention. BioDrugs 2001;15:595-607.
7. Lambris JD, Reid KB, Volanakis JE. The evolution, structure, biology and pathophysiology of complement. Immunol Today 1999;20:207-11.
8. Tracy R. Inflammation in cardiovascular disease: cart, horse or both? Circulation 1998;98:839-44.
9. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Circulation 1998;97:2259-67.
10. de Zwaan C, Kleine AH, Diris JHC, et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670-77.
11. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-4.
12. Sabatine MS, Antman EM. The Thrombolysis in myocardial infarction risk score in unstable angina /Non ST segment elevation myocardial infarction. J Am Coll Cardiol 2003;41(4 Suppl S): 89S-95S. Review.
13. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994;28:1301-11.
14. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 1994;28:437-44.
15. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 1995;268:448-57.
16. Collard CD, Vakeva A, Morrissey MA, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 2000;156:1549-56.
17. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971:133:885-900.
18. Nijmeijer R, Lagrand WK, Visser CA, et al. CRP, a major culprit in complement-mediated tissue damage in acute myocardial infarction? Internat Immunopharm 2001;1:403-14.
19. Pinckard RN, Olson MS, Giclas PC, et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975;3:740-50.
20. Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 1990;76:361-7.
21. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol 2000;278:747-57.
22. 2 supply and consumption in ischemic dog myocardium. Basic Res Cardiol 1987;82:57-65.
23. Zeitler H, Ko Y, Zimmermann C, et al. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction. Eur J Med Res 1997;2:389-94.
24. Yasuda K, Takeuchi M, Hiruma H, et al. The complement system in ischemic heart disease. Circulation 1989;81:156-63.
25. Michael R, Cusack MB, Michael S, et al. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002;39:1917-23.
26. Jan V, Jalan S, Aslam K, et al. Immune response in acute coronary syndromes. Indian Heart J 1999;51:515-20.
27. Leinoe E, Pachai A, Brandslund I. Complement activation reaches maximum during equilibrium between antigen and antibody in an in vitro model for thrombolysis with streptokinase. APMIS 2000;10:685-8.
28. Muscari A, Bozzoli C, Gerranta C, et al. Association of serum IgA and C4 with severe atherosclerosis. Atherosclerosis 1988;74:179-86.
29. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985;57:163-77.
30. Hergenc G. Role of complement system in atherosclerosis. Turk Kardiyol Dern Ar° 2004;32:28-37.
31. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999;19:2348-54.
32. Klouche M, Gottschling S, Gerl V, Hell W, et al. Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol 1998;18:1376-85.
33. Koenig W, Sund M, Frolich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-1992. Circulation 1999;99:237-42.
34. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996;157:473-79.
35. Yasuda M, Kawarabayashi T, Akioka K, et al. The complement system in the acute phase of myocardial infarction. Jpn Circ J 1989;53:1017-22.
36. Mollnes TE, Tambs KE, Myreng Y, Engebretsen LF. Acute phase reactants and complement activation in patients with acute myocardial infarction. Complement 1988;5:33-9.